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Background: Dynamic changes in Human Immunodeficiency Virus 1 (HIV-1) sequence diversity and divergence are
associated with immune control during primary infection and progression to AIDS. Consensus sequencing or single
genome amplification sequencing of the HIV-1 envelope (env) gene, in particular the variable (V) regions, is used as
a marker for HIV-1 genome diversity, but population diversity is only minimally, or semi-quantitatively sampled
using these methods.
Results: Here we use second generation deep sequencing to determine inter-and intra-patient sequence
heterogeneity and to quantify minor variants in a cohort of individuals either receiving or not receiving
antiretroviral treatment following seroconversion; the SPARTAC trial. We show, through a cross-sectional study of
sequence diversity of the env V3 in 30 antiretroviral-naive patients during primary infection that considerable
population structure diversity exists, with some individuals exhibiting highly constrained plasma virus diversity.
Diversity was independent of clinical markers (viral load, time from seroconversion, CD4 cell count) of infection.
Serial sampling over 60 weeks of non-treated individuals that define three initially different diversity profiles showed
that complex patterns of continuing HIV-1 sequence diversification and divergence could be readily detected.
Evidence for minor sequence turnover, emergence of new variants and re-emergence of archived variants could be
inferred from this analysis. Analysis of viral divergence over the same time period in patients who received short
(12 weeks, ART12) or long course antiretroviral therapy (48 weeks, ART48) and a non-treated control group revealed
that ART48 successfully suppressed viral divergence while ART12 did not have a significant effect.
Conclusions: Deep sequencing is a sensitive and reliable method for investigating the diversity of the env V3 as an
important component of HIV-1 genome diversity. Detailed insights into the complex early intra-patient dynamics of
env V3 diversity and divergence were explored in antiretroviral-naïve recent seroconverters. Long course
antiretroviral therapy, initiated soon after seroconversion and administered for 48 weeks, restricts HIV-1 divergence
significantly. The effect of ART12 and ART48 on clinical markers of HIV infection and progression is currently
investigated in the SPARTAC trial.
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Primary infection by Human Immunodeficiency Virus
type 1 (HIV-1) is usually initiated by a single or small
number of infecting virions [1]. Quantitative assessment
of HIV-1 evolution can be determined by measuring HIV
sequence diversity, the genetic variation at a given time,
and divergence, the genetic distance to a reference point,
usually the founder virus. In the absence of immune pres-
sure HIV-1 diversifies and diverges from the founder virus
by random mutation. This occurs during virus dissemin-
ation from the site of primary infection and the establish-
ment of a peak viremia [1]. Extensive viral diversity arises
from the high error rate of the HIV-1 reverse transcript-
ase, the rapid virus turnover, and the large population size.
Diversity is constrained upon initiation of the CD8 cyto-
toxic T lymphocyte (CTL) response [2]. Under intense
CTL selection, escape variants occur and expand within
the infectious virus pool. Single genome amplification
(SGA) sequencing and deep amplicon sequencing by
Roche/454 technology show many viral CTL escape var-
iants can exist in parallel at the time of declining viral load
and establishment of viral set point in both HIV and Sim-
ian Immunodeficiency virus (SIV) infections [3,4].
Longitudinal analysis of HIV-1 sequence variation fol-
lowing seroconversion shows virus divergence and diver-
sity accumulate co-linearly at approximately 1% per year
[5]. Sequence diversity increases, eventually plateaus,
and then in some cases declines over time. During the
diversity plateau, however, divergence continues to in-
crease until, at a later time, divergence stabilisation is
also reached [5]. The emergence of CXCR4-tropic var-
iants may occur immediately prior to the peak of diver-
sity, with stabilisation of divergence occurring during
periods of low CD4+ T cell numbers [5]. Although the
dynamics of HIV-1 diversity during primary infection
are well studied, less is known about the dynamics of di-
versity and divergence following seroconversion and
clinical latency, or the effect of antiretroviral therapy
(ART) on altering the course of diversification and diver-
gence. High HIV-1 envelope (env) diversity is linked to
slower disease progression and effective immune con-
trol. Specifically, Heteroduplex Tracking Assay (HTA)
analysis of populations of HIV-1 env V1/V2 and V4/V5
regions showed that high levels of sequence diversity
were linked with slower disease progression and that
rapid CD4+ T cell decline was associated with lower env
diversification [6]. Using the same assay over shorter
time intervals revealed that selective pressures on V1/V2
and V4/V5 are intense and continually evolving [7]. To-
gether this suggests that continued virus replication, in
the absence of drug therapy, but in the presence of adap-
tive immune responses drives divergence and diversity.
That intense selective pressure leads to HIV-1 muta-
tional escape has also been shown in the development ofantiviral drug resistance. Interestingly, recent data as
revealed by deep sequencing suggest that rather than
providing a strong selective pressure on the env gene
and constraining diversity, treatment with the CCR5
antagonist Vicriviroc resulted in V3 env diversity in-
creasing during treatment and was coupled with an ex-
pansion of rare sequence variants during drug resistance
selection [8]. This suggested that continued evolutionary
pressure resulted in the observable exploration of the
sequence space. Whether immune selective pressures
result in the same drive of diversification has not been
determined to the same detail by HTA which is a
semi-quantitative and non sequence based method. In
contrast, for patients on successful highly active anti-
retroviral therapy (HAART), an absence of evolution has
been shown for both the env C2-V3-C3 [9] and the pro-
tease encoding region [10]. However, these studies were
based on consensus and clonal sequencing, and did not
analyse the impact of the length of therapy on the diver-
sification and divergence of the virus.
Sequencing using second generation sequencing tech-
nology (Roche/454 Life Sciences) [11] has proven to be a
promising alternative to traditional clonal sequencing. It
surpasses the potential of clonal sequencing with regard
to sensitivity, throughput, and ability to quantify minor
variants. However, the drawbacks of a higher sequencing
error rate [8,12-14] and the potential generation of
recombinants during sample preparation by PCR [15,16]
have to be taken into account when minor variants are
analyzed. Deep sequencing of the env V3 loop has been
utilized in a limited number of chronically infected
patients to detect small minority X4-tropic viruses be-
fore [17] and during ART with a CCR5 antagonist [8], as
well as their emergence after interruption of this therapy
[18] or HAART [12].
Here, we show the application of deep sequencing of the
HIV-1 env V3 to determine the diversity of HIV-1 in
patients at primary infection with HIV-1 subtype B prior
to initiating ART. We show the detailed and complex
intra-patient dynamics of diversity and divergence follow-
ing primary infection. Importantly we provide evidence
that ART initiated soon after seroconversion can affect
the dynamics of HIV diversification and divergence.
Results
Sequence data and filtering
Deep sequencing data for the env V3 region of 80 patient
and 3 control samples were generated using 12 Genome
Sequencer FLX Instrument runs. Either 1/4 or 1/8 region
of a PicoTiterPlate was used for each pool of 5 to 12 sam-
ples. For one sample pool, sequencing yielded an average
of 34.13 MB (megabases) of total data from 115284 reads
with a read length of 297.87 ± 52.69 (mean ± SD). The
average number of initial reads generated was 13929
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19215) for control samples. Various filtering steps were
applied to the deep sequencing data (see Methods and
Additional file 1: Table S1). The resulting average se-
quencing depth for patient samples was 6908-fold
(354–29387). For the control sequences from cloned HIV
envelopes E6 and H8, the sequencing depth following data
filtering was 9783-fold (E6) and 15524-fold (H8); and for
the “mixed” HIV env control E6:H8, the sequencing depth
was 11491-fold. Phred quality scores for non-consensus
bases in the env V3 region were analysed for all samples
(Additional file 2: Figure S1). The median Phred score was
32.50 with a range of 21.17 to 39.86. Therefore, the me-
dian of the probability of a nucleotide being called incor-
rectly was 0.05% (range 0.76%–0.01%). However, as Phred
scores only account for base calling errors, we also
assessed the overall error rate of our entire amplification
and sequencing process.Figure 1 Sequence variants of the env V3 in patients at primary HIV i
found in 30 subjects at primary infection with HIV-1 subtype B and two co
sequenced env genes), are shown. Each bar represents one unique sequen
displayed.Error rates in 454 deep sequencing
In vitro transcribed RNA from two cloned and sequenced
env genes (E6 and H8) as well as a mixture of both (E6:
H8) with a molar ratio of 9:1 served as controls for total
processing error rates. Reverse transcription, nested
PCR, deep sequencing, assembly and data analysis were
performed as for the patient samples. In a first step,
process error rates were assessed using the controls E6
and H8. A total of 213 (E6) and 279 (H8) unique
sequences that diverged by one or more nucleotides from
the cloned env sequence were identified (Additional file 1:
Table S1), therefore of the total sequences obtained
90.89% (E6) and 92.08% (H8) were identical to the re-
spective plasmid sequence (Figure 1). The most frequent
minor variant which was not identical to the plasmid se-
quence obtained a frequency of 1.17% (E6) and 0.55%
(H8), respectively. For each of the 102 (E6) or 105 (H8)
nucleotide positions of the env V3 loop of the alignment,nfection and control samples. Major and minor sequence variants
ntrol samples, E6 and H8 (in vitro transcribed RNA from cloned and
ce variant. Only variants with frequencies above the 1.5% cut-off are
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nucleotides were correct, yielding the frequency of errors
introduced in the total sequencing process as 0.11% and
0.10%, respectively (Table 1). Mismatches rather than gaps
accounted for the majority of the errors within our data
processing pipeline. The sequence accuracy in non-
homopolymeric regions and homopolymeric regions,
defined as repeats of three or more identical bases and the
flanking non-identical bases [13], was compared. Errors
were more frequent in homopolymeric regions consistent
with the 454 technology, an average of 0.33% (E6) and
0.18% (H8) erroneous nucleotides were found here as
opposed to 0.07% in non-homopolymeric regions for both
clones.
Ratios of major and minor variants and the ability of
our methods to generate recombinant sequences were
also assessed by using the “mixed” control E6:H8 com-
bined at a ratio of 9 and 1. The two major sequence
variants were identical to the plasmid sequences of E6
(77.90% of the sequences) and H8 (11.86%). All
remaining sequences were present at low frequencies
of ≤ 0.40% (not shown). At least one recombinant
sequence was identified within these minor variants at a
very low frequency of 0.02% (2/11491 reads). A second
recombinant sequence with a frequency of 0.01%
(1/11491 reads) differed from the first only by an inver-
sion of two nucleotides at the end of a homopolymer
tract (not shown). Our error profile was almost identical
to that of Wang et al. [13], therefore using the same
Poisson model of 454 sequencing errors, we estimated
that we require a depth of greater than 750-fold to de-
tect a sequence present at 1.5%, and at that level we
were conservatively well in excess of both homopoly-
meric, non-homopolymeric, base calling errors and re-
combinant error rates.Table 1 Determination of sequence accuracy of control samp
Sequence accuracy Control E6
Mean M
Overall % correct nt 99.89 98
% erroneous nt 0.11 0.0
% mismatches 0.09 0.0
% gaps 0.02 0.0
Non-homopolymeric regions % correct nt 99.93 99
% erroneous nt 0.07 0.0
% mismatches 0.06 0.0
% gaps 0.01 0.0
Homopolymeric regionsa % correct nt 99.67 98
% erroneous nt 0.33 0.0
% mismatches 0.25 0.0
% gaps 0.08 0.0
a Repeats of 3 or more identical bases + flanking non-identical bases.Sequence diversity of the HIV env V3 at primary infection
Deep sequencing of the env V3 region of 30 patients at
primary infection with HIV-1 subtype B showed a complex
pattern of major and minor sequence variants (Figure 1).
The composition of major and minor variants differed be-
tween individuals with the major sequence variant account-
ing for up to 93.3% of the sequences (subject 15) or only
16.2% (subject 25). Between one (subjects 10, 15 and 30)
and 12 (subject 25) error corrected genuine sequence var-
iants (present at greater than 1.5% of the total sequences)
were found in each individual. Of note, for the individuals
with one major variant the sequences are effectively clonal.
Although frequencies of major and minor sequence
variants appear informative we wished to examine HIV-1
env sequence diversity in the more formal framework of
Shannon Entropy.
Coreceptor tropism of env V3 variants at primary
infection
Utilization of the CCR5 or CXCR4 receptor as an HIV
coreceptor was predicted based on env V3 variants of
the 30 patients as well as two control samples. Results of
predictions by (a) the PSSM method using the X4R5
matrix, (b) the PSSM method using the SINSI matrix
and (c) the Geno2pheno [coreceptor] tool are shown in
Additional file 3: Figure S2. For the majority of the var-
iants, CCR5 usage was predicted using all methods. Se-
quence variants associated with virus using the CXCR4
coreceptor were clearly identified in subject 18. The 2nd
(frequency 21.82%), 5th (3.29%) and 7th (1.82%) most fre-
quent variants were associated with CXCR4 coreceptor
usage, totaling 26.93% of the sequences found in this pa-
tient. CXCR4 coreceptor predictions were consistent for
the three methods for the variants with frequencies of
21.82% and 3.29%. For these two variants, PSSM scoresles
Control H8
inimum Maximum Mean Minimum Maximum
.37 100.00 99.90 98.96 100.00
0 1.63 0.10 0.00 1.04
0 1.61 0.07 0.00 0.48
0 0.94 0.03 0.00 0.70
.72 100.00 99.93 99.57 100.00
0 0.28 0.07 0.00 0.43
0 0.27 0.05 0.00 0.38
0 0.07 0.02 0.00 0.39
.37 99.99 99.82 98.96 100.00
1 1.63 0.18 0.00 1.04
1 1.61 0.11 0.00 0.48
0 0.94 0.07 0.00 0.70
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using the SINSI matrix were 1.93; the false positive rate
(FPR) for CXCR4 usage obtained by the Geno2pheno
[coreceptor] tool was 1.7%. However, for the variant with a
frequency of 1.82%, the PSSM SINSI matrix (score −0.45)
and the Geno2pheno [coreceptor] tool (FPR 1.5%)
predicted CXCR4 usage, while the PSSM X4R5 matrix
predicted a dual-tropic phenotype (score −6.88).
Env sequence diversity at primary infection is
independent of clinical markers of HIV infection
The Shannon Entropy was used as a metric for popula-
tion and sequence diversity, as it summarizes the num-
ber of sequence variants and their frequencies in a single
value. Accordingly, a strong correlation (R2 = 0.874) of
the Shannon Entropy with the number of sequence
variants identified for each individual was observed
(Additional file 4: Figure S3). In this inter-individual,
cross sectional analysis, the Shannon Entropy did not
correlate with the time from seroconversion (R2 = 0.011),
viral load (R2 = 0.013) or CD4 cell count (R2 = 0.001)
(Figure 2a, b, c). In addition, no correlation of theseFigure 2 Correlation of the Shannon Entropy with clinical
markers of HIV infection. The correlation with (a) the time after
seroconversion, (b) the viral load, and (c) the CD4 cell count is
shown for 30 subjects at primary infection with HIV. As the time to
seroconversion is not known for subject 15, it is not included in (a).
Patients were classified into three groups based on the sequence
diversity. Group 1 is defined by a low sequence diversity (Shannon
Entropy 0–0.75) and is shown as stars. Group 2 is defined by a
medium sequence diversity (Shannon Entropy 0.75–1.5) and is
shown as triangles. Group 3 is defined by a high sequence diversity
(Shannon Entropy > 1.5) and is shown as dots.parameters with the sequence depth was observed (not
shown, R2 between 0.001 and 0.149). Therefore, we arbi-
trarily assigned individuals into three groups based on
the Shannon Entropy as a measure for population com-
plexity. Group 1 was defined by low sequence diversity
at primary infection (Shannon Entropy 0–0.75), group 2
by a medium sequence diversity (Shannon Entropy
0.75–1.5), and group 3 by a high sequence diversity
(Shannon Entropy > 1.5) (Figure 2). From each of these
groups, we selected one non-treated individual where
serial samples were available to follow the change of di-
versity and divergence over time.
Dynamics of sequence diversity of the env V3 following
primary infection
We sequenced serial samples over ~ 60 weeks following
primary infection from three individuals of the non-
treated control group and used the Shannon Entropy as
a measure of sequence diversity. A general trend of in-
creasing population diversity was observed for two indi-
viduals (Subject 26 and 17). Subject 26 had the lowest
sequence diversity among all individuals at primary in-
fection (Shannon Entropy 0.13), where more than one
sequence variant was initially identified. Both the se-
quence diversity and the viral load in this subject fluctu-
ated over time, with an overall trend of increasing viral
load and sequence population diversity (Figure 3a). A
trend towards a correlation of the Shannon Entropy with
the viral load (not shown, R2 = 0.565) was observed. Sub-
ject 17 had ‘medium’ sequence diversity at primary infec-
tion. The sequence diversity after 60 weeks was
considerably higher than at primary infection. In con-
trast, the viral load declined over time (Figure 3b). Both
viral load and sequence diversity showed a transient
peak at day 266, however, overall the Shannon Entropy
did not correlate with viral load (not shown, R2 = 0.247).
Subject 25 had the highest sequence diversity among all
individuals following primary infection (Shannon En-
tropy 3.19). This degree of diversity was generally stable
over time (Shannon Entropy 3.03 after ~ 60 weeks) ex-
cept from a substantial decline in diversity at day 98
(Figure 3c). The viral load increased slowly over the time
course but with a strong transient peak at day 367. The
Shannon Entropy did not correlate with the viral load
(not shown, R2 = 0.002).
Dynamics of sequence divergence of the env V3 following
primary infection
We investigated sequence divergence of the serial sam-
ples of subjects 26, 17 and 25 by determining the genetic
distance of env V3 sequence variants at each time point
relative to the consensus sequence at the first time point
(Figures 4, 5 and 6). Pairwise genetic distances for each
variant and Neighbor-joining trees were used to visualise
Figure 3 Diversity and viral load over a time of ~ 60 weeks for
three subjects. The Shannon Entropy is used as a measure for
sequence diversity. Results are shown for (a) subject 26, with low
sequence diversity, (b) subject 17, with medium sequence diversity,
and (c) subject 25, with high sequence diversity at primary HIV
infection.
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time. Subject 26 had ‘low’ sequence diversity initially.
After the early divergence until day 8, sequence diversity
and divergence were then stable over 320 days (Figure 4).
Interestingly, the major variant present at day 419appeared to be a re-emergence of the dominant se-
quence variant detected immediately post seroconver-
sion. In addition the minor sequence variants present at
day 419 were also closely related, but distinct from the
variants present at day 8. Subject 17 who had a ‘medium’
sequence diversity following primary infection showed a
slow but continuously increasing divergence from the
consensus virus over 420 days (Figure 5b) with the later
time points showing the outgrowth of a distinct HIV
population (Figure 5c). It is also clear that early, post
seroconversion plasma virus variants are not present as
detectable minority species at day 420 and that little se-
quence diversification occurred between days 49 to 266.
Subject 25 had ‘high’ sequence diversity at primary infec-
tion, and sequence divergence continued over 421 days
(Figure 6). Visualisation using Neighbor-joining trees
coupled with frequency analysis revealed a complex biol-
ogy in this individual. Two genetically distinct popula-
tions (I and II) were seen at early time points, both of
which continued to diversify and diverge over 421 days.
No evidence of recombinant sequences was observed.
The frequencies of the two populations were similar up
to day 35 and between day 175 and 421. Interestingly, a
transient dominant variant with a frequency of 65%
arose from population I at 98 days and whilst later var-
iants in group I were related to this variant it did not
lead to a complete population turnover and commensur-
ate decrease in the frequency of group II variants at later
times. After analysing the dynamics of sequence diversity
and divergence in these three non-treated individuals in
detail, we sought to explore the impact of ART on viral
diversification and divergence over time in all 30
patients.
Influence of ART on the divergence of the viral
population
The trial SPARTAC was designed to assess the clinical impact
of short course (12 weeks, ART12) and long course (48 weeks,
ART48) antiretroviral therapy initiated soon after seroconver-
sion. To analyse the effects of ART12 and ART48 on the di-
vergence of the viral population, (i.e. to assess how far the
population has evolved from the founder virus), mean root to
tip distances for sequences from each patient over a time of
~ 60 weeks were analysed and compared between the arms of
the study (Figure 7). This time point corresponds to 12 weeks
after the end of ART in the ART48 group, and 48 weeks after
the end of ART in the ART12 group. Viral loads at ~ 60 weeks
after primary infection had rebounded close to viral loads at
primary infection in all subjects, with no significant differences
in viral load between the non-treated control group and
ART12 (p=0.248), the control group and ART48 (p=0.211)
or ART12 and ART48 (p= 0.497) (Additional file 5: Figure
S4). The divergence after ART48 was significantly lower com-
pared to ART12 (p=0.019) or the non-treated control group
Figure 4 (See legend on next page.)
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Figure 4 Sequence variants of the env V3, divergence and Neighbor-joining tree for subject 26. Samples over a time of ~ 60 weeks were
analysed; with day 0 shown in black, and a rainbow colour scheme ranging from orange to pink applied to the remaining time points. (a)
Sequence variants of the env V3. Each bar stands for one unique sequence variant. Only variants with frequencies above the 1.5% cut-off are
displayed. (b) Divergence of env V3 sequence variants. Divergence is shown as the pairwise genetic distance (number of nucleotide substitutions
per site) of a sequence variant at a given time from the consensus sequence at time 0. Genetic distances were estimated under the General Time
Reversible model of nucleotide substitution, with proportion of invariable sites and gamma-distributed rate heterogeneity (GTR + I + G). Sizes of
the circles around the symbols represent the frequencies of the sequence variants. The largest circle at each time point marks the major variant;
the 2nd, 3rd and 4th most abundant variants are shown with gradually smaller circles; from the 5th most abundant variant circles have the same
size. Note that the scale of the y-axis in this figure is different from Figures 5 and 6. (c) Neighbor-joining tree of env V3 sequence variants. The
tree was reconstructed under the GTR + I + G model of nucleotide substitution. Branches are labeled with frequencies of sequence variants as
depicted in (a). The scale bar represents the number of nucleotide substitutions per site.
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between ART12 and the control group (p=0.780).Discussion
Deep sequencing using second generation sequencing
technology [11] offers unprecedented possibilities to rap-
idly generate large and quantitative data and to detect
minor variants of pathogens. Elucidation of the error rates
of our procedures shows they are consistent with previous
studies [13] with per-nucleotide error rates of 0.11% and
0.10%, respectively, for the new GS FLX Titanium chemis-
try. We determined that under our conditions recombin-
ant sequences were observed less frequently, 3/11491
(0.03%) than the 0.11% and 0.15% found by Tsibris et al.
[8]. Understanding the error associated with the entire se-
quencing process allowed the reliable analysis of sequence
variants of the env V3 in a cross-sectional study of 30
patients at primary HIV infection. Our per-nucleotide
error rate allowed the derivation of a frequency of detec-
tion for the least abundant sequence above experimental
errors. This was defined as a frequency of 1.5%, and there-
fore all minor variants with frequencies above this cut-off
were considered to be true variants.
The degree of sequence diversity of the env V3 was con-
siderable among patients, with the proportion represented
by the major variant ranging from 93.3% and 16.2% of the
sequenced population. Although amplification was per-
formed using primers in conserved regions of env, we can-
not exclude the possibility of cis-linkage between the
primer binding sites and the V3 region biasing our mea-
sures of diversity by preferentially amplifying one or more
variants. Nevertheless our data are consistent with HTA
assays which also revealed strong ‘monoclonal’ env bands
in a number of individuals during early HIV infection
[6,7]. Coreceptor usage prediction revealed that more than
¼ of the env V3 variants in subject 18 at primary infection
were predicted as capable of using the CXCR4 coreceptor.
Deep env V3 sequencing is therefore a valuable tool for
the sensitive and quantitative assessment of HIV diversity
and divergence as well as coreceptor tropism at primary
infection [3].Intra-individual differences in HIV population diver-
sity are apparent at primary infection and here we arbi-
trarily assigned individuals into 3 diversity groups (low,
medium and high) based on Shannon Entropy. The de-
gree of HIV sequence diversity has been associated with
CD4 counts later in infection [6]. Here, however, we
were unable to correlate viral load, time from serocon-
version, or CD4 counts with the frequency of sequence
variants or the Shannon entropy of each individual’s
HIV-1 env V3 population. As the patients included in
this study were selected based on their detectable viral
loads (average 223,737 RNA copies per ml at baseline),
1 ml plasma was used for RNA extraction and 10 μl
RNA were used for the initial one-step RT-PCR, it is
unlikely that a bias in sequence diversity was due to
undersampling of the virus population during sample
processing. However, it is clear that a 1 ml plasma sam-
ple from an adult represents only a fraction of the total
blood volume of ~ 5 liters. In addition, focusing on post
seroconversion samples may be too short a time frame
to see longer term correlations with these other mea-
sures of HIV replication. Limiting the analysis to the env
V3 may affect the power to find correlations with clin-
ical markers of HIV infection.
Serial sampling of three individuals with high, medium
and low diversity following primary infection suggests
that increases in diversity and divergence from the virus
present immediately following primary infection oc-
curred as previously described [5], and these properties
are detectable even over 60 weeks of sampling. The
depth of sequencing obtained in our study allowed a
much greater insight into the HIV population dynamics
of these three individuals than it could be achieved by
clonal sequencing. Subject 26, classed as low initial se-
quence diversity showed minimal increase in HIV diver-
gence over time. Interestingly, at 419 days the re-
emergence of variants occurred that were identical or
closely related to variants present immediately post sero-
conversion. If this represents re-emergence from an
archived provirus pool or the emergence of a variant
continuously replicating in a different reservoir but
excluded from the peripheral blood until day 419 is not
Figure 5 Sequence variants of the env V3, divergence and Neighbor-joining tree for subject 17. Samples over a time of ~ 60 weeks were
analysed; with day 0 shown in black, and a rainbow colour scheme ranging from orange to pink applied to the remaining time points. The
remaining details are as per Figure 4.
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Figure 6 Sequence variants of the env V3, divergence and Neighbor-joining tree for subject 25. Samples over a time of ~ 60 weeks were
analysed; with day 0 shown in black, and a rainbow colour scheme ranging from orange to pink applied to the remaining time points. The
remaining details are as per Figure 4.
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Figure 7 Influence of ART on the divergence of the viral
population. Each group contains 10 individuals. Control, non-
treated individuals; ART12, short course antiretroviral therapy
(12 weeks); ART48, long course antiretroviral therapy (48 weeks). The
divergence is shown as mean intra-patient root to tip distance,
defined as genetic distance (in number of nucleotide substitutions
per site) from each sequence to the root. Distances were calculated
under the uncorrected (p) model of nucleotide substitution (number
of substitutions accumulated along the path from the tip to the
root, divided by the length of the alignment). Root to tip distances
were analysed over a time of ~ 60 weeks after primary infection. The
significance of differences in the mean between groups was tested
by Wilcoxon rank sum tests. There is no significant difference
between the control group and ART12 (p = 0.780).
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mented following interruption from prolonged HAART
[19,20], and deep sequencing of provirus populations
from macrophages indicates higher and distinct HIV di-
versity than T lymphocytes [12]. It is likely therefore that
combined deep sequence analysis of viral and proviral
populations at primary infection will reveal more details
of the intra-individual HIV evolution over time. Subject
17, classified with initial medium sequence diversity had
an uncomplicated pattern of increasing HIV sequence
divergence, and the emergence of different diverse popu-
lations over time, in agreement with previous analysis
[5]. Subject 25, classed as high initial sequence diversity
showed evidence of two distinct HIV populations at pri-
mary infection. Both virus lineages persisted following
primary infection suggesting they are representative of
viruses with equivalent fitness. Whether they represent
the result of transmission of more than a single virus as
has been observed in approximately 25% of primary in-
fection [1], or are the result of a super-infection during
seroconversion cannot be determined by deep sequen-
cing of the env V3. Furthermore, no conclusions can bemade about the other 27 subjects, as only two samples
were analysed for each of these subjects.
As HIV sequence divergence is affected by immune re-
sponse and antiviral therapy, we determined if differences
in divergence were observable at ~ 60 weeks after primary
infection in individuals on the short (12 weeks, ART12) or
long (48 weeks, ART48) course antiviral therapy following
seroconversion. The divergence of the population from
the founder virus was significantly lower after ART48 than
in the non-treated control group, consistent with the suc-
cessful suppression of HIV-1 evolution during HAART as
previously reported [9,10]. In contrast, ART12 did not
have a significant effect on the divergence at ~ 60 weeks
after primary infection. As viral loads are not significantly
different on both treatment arms at ~ 60 weeks after pri-
mary infection, the observed difference in divergence be-
tween ART12 and ART48 most likely reflects prolonged
virus replication inhibition in the ART48 arm. Therefore,
virus divergence at ~ 60 weeks after primary infection pro-
vides a measure of the previous extent of antiretroviral
suppression of HIV replication. These observed differ-
ences are unlikely to remain with continued virus replica-
tion in the absence of antiretroviral therapy. Whether
more short lived effects on the ART12 arm are visible at
earlier times is not clear, however the HIV evolutionary
properties analysed here suggest a lack of efficacy of
ART12 in the prolonged alteration of HIV evolutionary
dynamics. Whether ART12 affects clinical markers of HIV
infection and progression in the framework of the SPAR-
TAC trial is currently under investigation.
Conclusions
We conclude, after analysis of 80 patient samples and ap-
propriate controls, that deep sequencing of the HIV-1 env
V3 can successfully be applied to ascertain HIV-1 diversity
in clinical settings. It shows detailed and complex intra-
patient dynamics of env V3 diversity and divergence follow-
ing primary infection. Importantly, we found that long
course antiretroviral therapy for 48 weeks (ART48), initiated
soon after seroconversion, clearly produces a measurable
difference in HIV sequence evolution. Such therapy may
therefore have a more pronounced impact on markers of
HIV infection and progression than short course antiretro-
viral therapy (ART12). Our analysis of the env V3 as a mar-
ker for HIV-1 genome diversity is, therefore, informative in
detecting HIV-1 treatment effects.
Methods
Subjects
Thirty study subjects diagnosed with primary HIV-1 in-
fection (PHI) were selected from the Short Pulse Anti-
retroviral Therapy at Seroconversion (SPARTAC) study.
PHI was confirmed by one of the following criteria: i)
positive HIV-1 serology following a negative test within
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HIV-1 ELISA, iii) rising antibody levels detected by pro-
gression of protein bands on Western blot, or iv) posi-
tive HIV-1 proviral PCR or p24-antigen ELISA in the
absence of HIV-1 specific antibodies [21]. The partici-
pants studied longitudinally were randomised three
ways, to no therapy (Control) or 12 weeks (ART12) or
48 weeks (ART48) antiretroviral therapy shortly after
seroconversion, with 10 subjects in each group. Only
subjects with plasma viral loads greater than 30,000
RNA copies per ml at enrolment were selected for study.
Samples collected at enrolment from subjects E6 and
H8, who were not included in deep sequencing studies,
were used to construct cloned HIV-1 envelopes for use
as sequencing controls.
Viral RNA extraction
Viral RNA was extracted from EDTA plasma collected
at enrolment and after ~ 60 weeks from all subjects, and
longitudinally over ~ 60 weeks from three subjects, using
a QIAamp Viral RNA Mini Kit (Qiagen, Crawley, UK).
Briefly, 1 ml of EDTA treated plasma was centrifuged
for 1 hour at 25,000 g. The resultant pellet was resus-
pended in 140 μl nuclease-free phosphate buffered saline
before continuing with the RNA purification according
to the manufacturer’s instructions. RNA was eluted in
50 μl of elution buffer.
In vitro transcription
Full length HIV-1 env was reverse transcribed and PCR
amplified from plasma viral RNA from subjects E6 and
H8 using primers EnvF (50-GGG CTC GAG GCG GCC
GCG AGC AGA AGA CAG TGG CAA TG-30) and
EnvR (50-AAA TCT AGA GGG CCC CCA CTT GCC
ACC CAT RTT A-30). Amplified env genes were cloned
into pcDNA3.1 (+) using restriction sites ApaI and XbaI.
Single clones were purified from transformed MACH I
strain E.coli using a GeneJET™ Plasmid Miniprep Kit
(Fermentas, York, UK). Eight micrograms of each plas-
mid were linearised with 50 units of ApaI restriction en-
zyme and digested DNA was purified using a GeneJET™
Gel Extraction Kit (Fermentas). One-hundred nanograms
of purified DNA were transcribed with T7 polymerase
(Invitrogen, Paisley, UK) in the supplied buffer supplemen-
ted with 0.4 mM of each nucleotide, 100 ng/μl BSA (New
England Biolabs, Hitchen, UK), 2 units/μl of RNaseOUT™
Ribonuclease Inhibitor (Invitrogen) and in the presence of
5 mM DTT. Reactions were incubated for 2 hours at 37°C.
Template DNA was digested with one unit of DNAase I
(Invitrogen) at 37°C for 30 min and reactions were termi-
nated with a final concentration of 2.5 mM EDTA (pH 8.0)
for 10 min at 65°C. Transcripts were purified using an
RNeasy kit (Qiagen) with on-column DNase digestion
according to the manufacturer’s instructions. The integrityand quantity of RNA was determined using a Bioanalyzer
2100 (Agilent Technologies, Wokingham, UK). Elimination
of DNA template was confirmed by quantitative real-time
PCR using SYBR Green PCR master mix (Sigma Aldrich,
Gillingham, UK), which did not produce a fluorescent
signal after 35 amplification cycles in a LightCycler 2.0
(Roche Applied Science, Lewes, UK).
Reverse transcription and nested polymerase chain
reaction
Viral RNA and in vitro transcribed RNA were reverse tran-
scribed and PCR amplified in a single-tube reaction using
SuperScriptW III One-Step RT-PCR System with PlatinumW
Taq High Fidelity (Invitrogen). Each 50 μl reaction contained
200 nM of primer CV1 (50-TAA CAT GTG GAA AAATAA
CAT GGT-30), 200 nM of primer CV4 (50-AGA AAA ATT
CTC CTC CAC AAT TAA A-30) and 10 μl plasma RNA ex-
tract or 104 copies of RNA transcript. Cycling conditions were
55°C for 30 min (reverse transcription), 94°C for 2 min (hot
start), 35 cycles of 94°C for 30 s, 55°C for 30 s, 68°C for 30 sec-
onds, and a final incubation at 68°C for 5 min. Second round
PCR was performed using PhusionW Hot Start High-Fidelity
DNA Polymerase (Finnzymes). Each 25 ul reaction contained
12.25 ul Nuclease-Free Water, 5 ul PhusionW HF Buffer (5x),
0.5 ul dNTP mix (10 mM each), 1 ul each of primers JAE1
(50-CAC AGT ACA ATG TAC ACA TG-30) and JAE4 (50-
ACA ATT TCT GGG TCC CCT CC-30) (20 pmol/ul), 0.25
ul PhusionW Hot Start DNA Polymerase (2 U/μl) and 5 ul of
template first round PCR product. Cycling conditions
were 98°C for 30 s (initial denaturation), 40 cycles of 98°C
for 10 s, 60°C for 20 s, 72°C for 15 s, and a final incubation
at 72°C for 10 min. Amplicons with a size of 387 bp were
visualized by 2% agarose gel electrophoresis for 1 h at
120 V in Tris-acetate-EDTA buffer.
Deep sequencing of amplicons
Nested PCR amplicons were sequenced without further
purification using the Genome Sequencer FLX Instrument
and GS FLX Titanium series reagents (Roche/454 Life
Sciences) according to the manufacturer’s instructions. In
short, single-stranded DNA libraries were prepared with
the GS FLX Titanium Rapid Library Preparation Kit, using
one of the 12 Multiplex Identifier (MID) adaptors for each
sample. Between 5 and 12 libraries were pooled and immo-
bilized onto DNA capture beads. Clonal amplification was
carried out by emulsion PCR. Emulsions were broken,
beads were enriched, loaded onto 1/4 or 1/8 of a PicoTiter-
Plate and sequencing-by-synthesis was performed [11].
Read assembly and filtering
One SFF file per region of the PicoTiterPlate was gener-
ated by the Genome Sequencer FLX System Software
(Roche/454 Life Sciences). Using the sfffile and sffinfo
commands of the SFF tools, the SFF file was split into separate
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quence reads for each sample were created. Sequence reads
were mapped against a HIV-1 subtype B env sequence which
matched the samples with regard to the country of origin
(UK) and the collection date (2005) [GenBank: FJ653428]
using the software Segminator [18,22]. Thereby reads with a
length < 70 nt and/or low identity to the reference sequence
were removed. The pipeline for data processing, filtering and
assembly is summarised in Additional file 6: Figure S5. Align-
ments were trimmed to the env V3 region and visually
inspected in BioEdit version 7.0.9.0 [23]. All reads not span-
ning the entire env V3 region as well as misaligned reads were
removed. To obtain a final alignment, reads containing
‘Ns‘were removed, as these correspond to positions where no
nucleotide was incorporated during sequencing in greater than
three consecutive flows. Additional file 1: Table S1 summarizes
how many sequences were discarded at each step of the filter-
ing process. Subsequently, duplicate sequences were elimi-
nated with the ElimDupes tool [24] which generated an
alignment comprising only the unique sequences found in
each sample, and a table showing the numbers and names of
the duplicates represented by each unique sequence. Frequen-
cies of sequence variants as well as process error rates for the
control samples were calculated and the most frequent unique
sequences within each sample were extracted from the align-
ments with a combination of Excel and customized python™
scripts. All figures were computed in R version 2.10.1 [25].
Recombination analysis
The Highlighter tool [26] was used to visualize alignments
and to screen for recombinant sequences. These were veri-
fied with the manual bootscan method [27] implemented in
the Recombination Detection program version 3.42 [28,29].
Shannon information entropy
Sequence diversity was assessed by measuring the Shannon
information entropy [30] and calculated with a customized
R script. Shannon Entropy at time t is defined as
S tð Þ ¼ 
XN tð Þ
i¼1
fi tð Þlog2 fi tð Þ
where N(t) is the number of unique sequence variants that
are present at time t, and fi (t) is the proportion of the i
th se-
quence variant [4]. The more diverse the variants present
in amounts comparable to one another, the greater the
resulting entropy value.
Genetic distance and divergence analysis and Neighbor-
joining trees
To analyse the dynamics of sequence divergence of the env
V3 following primary infection in three patients in detail,
sequence divergence was calculated as the pairwise geneticdistance (number of nucleotide substitutions per site) of a
sequence variant at a given time from the consensus se-
quence at time 0. Prior to computation, the appropriate
model of nucleotide substitution was determined using
jModelTest version 0.1.1 [31]. Genetic distances were esti-
mated under the General Time Reversible model of nucleo-
tide substitution, with proportion of invariable sites and
gamma-distributed rate heterogeneity (GTR+ I +G), using
PAUP* version 4.0b10 [32] and Neighbor-joining trees were
reconstructed under the same model. Trees were edited
with the program FigTree version 1.3.1 [33].
To explore the impact of ART on divergence of the viral
population over time in all 30 patients, mean intra-patient
root to tip distances, defined as genetic distance (in number
of nucleotide substitutions per site) from each sequence to
the root, were used. Distances were calculated under the un-
corrected (p) model of nucleotide substitution using PAUP*
version 4.0b10. The null hypothesis that the root to tip
distances are equal in the three groups was tested using
Wilcoxon rank sum tests using R version 2.10.1.
Coreceptor usage prediction
Coreceptor usage of sequence variants was predicted
using both position-specific scoring matrices (PSSM)
[34] and support vector machines (SVM) implemented
in the Geno2pheno [coreceptor] tool [35].
Accession numbers for sequencing data
The Roche/454 Life Sciences sequencing data obtained in this
study is available from the EMBL/GenBankW/DDBJ Sequence
Read Archive under study accession number ERP001147.Additional files
Additional file 1: Table S1. Read numbers in data analysis steps.
Additional file 2: Figure S1. Phred quality scores of non-consensus
bases in the env V3 region. Data from 80 patient samples and 3 control
samples were analysed by determining the median, interquartile range
and maximum/minimum Phred scores for each nucleotide in each
sequence with each boxplot representing one sample. No boxplots are
shown for 3 patient samples and 2 control samples, as no minor variants
above the 1.5% frequency cut-off were found in these. The median Phred
quality score was 32.50 with a range from 21.17 to 39.86.
Additional file 3: Figure S2. Coreceptor usage prediction for the env
V3 variants in patient and control samples. Predictions were made for the
12 most frequent sequence variants found in each of the 30 patients as
well as the two control samples by (a) the PSSM method applying the
X4R5 matrix and (b) the SINSI matrix or (c) the Geno2pheno [coreceptor]
tool. The colour of the fields in (a) and (b) represents the determined
PSSM scores ranging from association with CCR5 usage (red) or CXCR4
usage (white) or in (c) the false positive rate of the prediction of CXCR4
usage. The black line stands for the cut-off defined in this study: based
on analysis of the control samples, minor variants with frequencies of
> 1.5% are considered to be true. *, sequence contains a stop codon.
Additional file 4: Figure S3. Correlation of the Shannon Entropy with
the number of sequence variants. The correlation is shown for 30
subjects at primary infection with HIV. Patients were classified into three
groups based on the sequence diversity. Group 1 is defined by a low
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Group 2 is defined by a medium sequence diversity (Shannon Entropy
0.75–1.5) and is shown as triangles. Group 3 is defined by a high
sequence diversity (Shannon Entropy > 1.5) and is shown as dots.
Additional file 5: Figure S4. Viral load at ~ 60 weeks after primary
infection with HIV. Each group contains 10 individuals. Control, non-
treated individuals; ART12, short course antiretroviral therapy (12 weeks);
ART48, long course antiretroviral therapy (48 weeks). The significance of
differences in the mean between groups was tested by Wilcoxon rank
sum tests. There is no significant difference between the non-treated
control group and ART12 (p = 0.248), the control group and ART48
(p = 0.211) or ART12 and ART48 (p = 0.497).
Additional file 6: Figure S5. Data processing, filtering and assembly.
Workflow for data analysis of 454 short read amplicons.
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